19 November 2021. TCRCure have received Investigational New Drug (IND) approval from the CENTER FOR DRUG EVALUATION, NMPA (the “CDE”)for the Phase 1/2 clinical study of Modified autologous T cells for targeting HPV and delivery of anti-PD-1 in the treatment of HPV-positive recurrence and metastasis cervical cancer.

TCRCure Biopharma Ltd. Conducts Investigator Meeting in Preparation for New Cervical Cancer Drug Study for TC-E202 (1st IND approved PD-1 antibody armed TCR-T compound in the world)